PHARMACEUTICAL VETERINARIAN PREPARATIONS

Brand Owner (click to sort) Address Description
ENTOMOPHARM Entomopharm ApS Lundekaersvej 33 DK-5250 Odense SV Denmark Pharmaceutical and Veterinarian preparations for use in blood brain barrier screening to determine the biomembrane permeability for the treatment of depression, schizophrenia, chronic pain, epilepsy, cancer, spinal cord trauma, neurological diseases, Huntington's disease, blood-brain barrier related malfunctions, obesity, fungal infections, A.L.S., multiple sclerosis, neuro-AIDS, progressive multifocal leukoenceplalopathy, autism, lysosomal storage disorders, fragile X syndrome, inherited mental retardation, inherited ataxias, prion disease, meningitis, neuromyelitis optica, late-stage neurological trypanosomiasis, parasitic diseases, De Vivo disease, rabies, encephalitis, locked-in syndrome and bacterial infections;ENTOMO PHARMACEUTICAL;Agriculture advice; Forestry services, namely, vermin and pest control services; forest habitat restoration;Scientific, technological and industrial services, namely, scientific research, analysis, testing in the field of pharmaceutical and drug development; Industrial analysis and research services for human and veterinarian pharmaceuticals;
LAITOGEN OPERADORA ATRIUM, S.A. DE C.V. AV. VALLARTA 1312, COL. AMERICANA GUADALAJARA 44160 Mexico Pharmaceutical and veterinarian preparations for treatment of intestinal bacteria; pharmaceutical health preparations for wounds; baby foods; medical use plaster; bandages for dressings: tooth filling; dental tooth wax; disinfectants for hygienic purposes; fungicides, herbicides; vitamins; food supplements;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for treating secretory diarrhea. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients, and/or diluents.